Comprehensive Report on the Small Molecule Drug Discovery Market: Opportunities and Challenges

 This study helps professionals make sense of complex market trends and competitive shifts affecting the small molecule drug discovery industry today.

What Is The Expected CAGR For The Small Molecule Drug Discovery Market Through 2025?
The small molecule drug discovery market size has grown strongly in recent years. It will grow from $62.44 billion in 2024 to $67.94 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to drug repurposing initiatives, automation in drug discovery, increased investment in r&d, regulatory support for drug development, advancements in high-throughput screening.

The small molecule drug discovery market size is expected to see rapid growth in the next few years. It will grow to $104.6 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to emergence of novel therapeutic targets, patient-centric drug discovery, drug-device combination products, real-world evidence utilization, pharmacogenomics integration, global health challenges. Major trends in the forecast period include fragment-based drug discovery, integration of artificial intelligence in drug discovery, rna-targeted therapeutics, collaborations and partnerships, innovations in drug delivery, adoption of organoids and 3d cell culture models.

Get your free sample today:
Small Molecule Drug Discovery Market Report 2025, Size And Share Sample

Which Key Factors Will Influence Small Molecule Drug Discovery Market Growth Over 2025-2034?
The rising incidence of chronic diseases is expected to boost the growth of the small molecule drug discovery market going forward. Chronic diseases refer to conditions that last for a year or longer, hinder everyday activities, demand continuous medical care, or both. Small-molecule medications can be used to treat chronic conditions like HIV, cancer, infections, heart disease, and renal disease, and these medications are generally more economical for patients with chronic conditions. Hence, the rising incidence of chronic diseases is expected to boost the small molecule drug discovery market. For instance, according to a report published by the National Institutes of Health (NIH), a US-based biomedical research agency, in 2023, in the United States, the number of people aged 50 and older with at least one chronic illness is predicted to rise by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Additionally, the number of people with multimorbidity would rise by 91.16% from 7.8304 million in 2020 to 14.968 million in 2050. Therefore, the rising incidence of chronic diseases is driving the growth of the small molecule drug discovery market.

Comprehensive Segment-Wise Insights Into The Small Molecule Drug Discovery Market
The small molecule drug discovery market covered in this report is segmented –

1) By Drug Type: Small Molecule Drugs, Biologic Drugs
2) By Technology: High Throughput Screening, Pharmacogenomics, Combinatorial Chemistry, Nanotechnology, Others
3) By Therapeutic Area: Oncology, Central Nervous System, Cardiovascular, Respiratory, Metabolic Disorders, Gastrointestinal, Others
4) By Process Or Phase: Target ID Or Validation, Hit Generation And Selection, Lead Identification, Lead Optimization
5) By End-User: Pharmaceutical Companies, Contract Research Organizations, Others

Subsegments:
1) By Small Molecule Drugs: Generic Small Molecule Drugs, Novel Small Molecule Drugs
2) By Biologic Drugs: Monoclonal Antibodies, Vaccines, Recombinant Proteins, Cell And Gene Therapies

What Are The Future Trends Of The Small Molecule Drug Discovery Market?
Technological innovations are the key trend gaining popularity in the small molecule drug discovery market. Major companies operating in the small molecule drug discovery market are focusing on developing new products. For instance, in January 2023, Dotmatics, a US-based provider of digital science platform, launched Small Molecule Drug Discovery Solution. It is uniquely designed with integrated scientific R&D platform that has pre-configured workflows and expanded data management capabilities. It reduces the operational inefficiencies, and speeds the process of taking data from insights to decisions.

Analysis Of Key Players In Small Molecule Drug Discovery Market
Major companies operating in the small molecule drug discovery market include Pfizer Inc., GlaxoSmithKline plc, AstraZeneca, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, Gilead Sciences Inc., Merck KGaA, Novartis AG, 4SC AG, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Labcorp Drug Development, ICON Public Limited Company, Charles River Laboratories, Aluda Pharmaceuticals, Clinuvel Pharmaceuticals, Corcept Therapeutics, Edison Oncology, Escend Pharmaceuticals, Terray Therapeutics, Apollomics, Astex Pharmaceuticals, Pardes Biosciences, Xynomic Pharmaceuticals, Zevra Therapeutics, UNION therapeutics, Pharmacosmos, Allarity Therapeutics, Xellia Pharmaceuticals, Cyteir Therapeutics, BigHat Biosciences

View the full small molecule drug discovery market report here:
Small Molecule Drug Discovery Market Report 2025, Size And Share

What Are The Key Regional Trends In The Small Molecule Drug Discovery Market?
North America was the largest region in the small molecule drug discovery market in 2024. Europe is expected to be the fastest-growing region in the small molecule drug discovery market report during the forecast period. The regions covered in the small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:

The Business Research Company

Market Research Reports

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: The Business Research Company | LinkedIn